These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 21179101

  • 1. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R, Zoppi A, Salvadeo SA, Mugellini A, Lazzari P, Santoro T, Derosa G.
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [Abstract] [Full Text] [Related]

  • 2. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
    Fogari R, Zoppi A, Mugellini A, Maffioli P, Lazzari P, Derosa G.
    Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibition and fibrinolytic balance.
    Matsumoto T, Horie M.
    Hypertens Res; 2011 Apr; 34(4):448-9. PubMed ID: 21326308
    [No Abstract] [Full Text] [Related]

  • 4. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD, Iberian Multicenter Imidapril Study on Hypertension.
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [Abstract] [Full Text] [Related]

  • 5. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH, SOT-AT1 Study Group.
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [Abstract] [Full Text] [Related]

  • 6. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.
    Clin Drug Investig; 2007 Mar; 27(6):407-17. PubMed ID: 17506591
    [Abstract] [Full Text] [Related]

  • 7. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
    Hirschl MM, Bur A, Woisetschlaeger C, Derhaschnig U, Laggner AN.
    J Clin Hypertens (Greenwich); 2007 Jun; 9(6):430-5. PubMed ID: 17541328
    [Abstract] [Full Text] [Related]

  • 8. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M, Cincin A, Baykan OA.
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [Abstract] [Full Text] [Related]

  • 9. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
    Fogari R, Zoppi A, Mugellini A, Lazzari P, Derosa G.
    Horm Metab Res; 2010 Nov; 42(12):892-6. PubMed ID: 20814848
    [Abstract] [Full Text] [Related]

  • 10. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
    Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK.
    Int J Cardiol; 2006 Mar 22; 108(1):96-100. PubMed ID: 16246439
    [Abstract] [Full Text] [Related]

  • 11. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
    Skurk T, Lee YM, Nicuta-Rölfs TO, Haastert B, Wirth A, Hauner H.
    Diabetes Obes Metab; 2004 Jan 22; 6(1):56-62. PubMed ID: 14686964
    [Abstract] [Full Text] [Related]

  • 12. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
    Yajima K, Shimada A, Hirose H, Oikawa Y, Yamada S, Meguro S, Irie J, Irie S.
    Clin Drug Investig; 2009 Jan 22; 29(12):811-9. PubMed ID: 19888787
    [Abstract] [Full Text] [Related]

  • 13. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE.
    Am J Hypertens; 2008 Feb 22; 21(2):172-6. PubMed ID: 18188164
    [Abstract] [Full Text] [Related]

  • 14. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
    Fogari R, Derosa G, Lazzari P, Zoppi A, Fogari E, Rinaldi A, Mugellini A.
    Am J Hypertens; 2004 Sep 22; 17(9):823-7. PubMed ID: 15363826
    [Abstract] [Full Text] [Related]

  • 15. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.
    J Hypertens; 2005 Feb 22; 23(2):435-44. PubMed ID: 15662233
    [Abstract] [Full Text] [Related]

  • 16. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
    Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A.
    Am J Hypertens; 2007 Oct 22; 20(10):1092-6. PubMed ID: 17903693
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive drugs and fibrinolytic function.
    Fogari R, Zoppi A.
    Am J Hypertens; 2006 Dec 22; 19(12):1293-9. PubMed ID: 17161777
    [Abstract] [Full Text] [Related]

  • 18. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G, Schmieder R, Calvo C, Asmar R.
    Am J Hypertens; 2006 Jan 22; 19(1):113-21. PubMed ID: 16461202
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G, Ferrara L, Tagliamonte E, Russo PE, Di Benedetto A, Iacono A.
    Cardiologia; 1999 Dec 22; 44(12):1071-6. PubMed ID: 10687258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.